Memorial Sloan Kettering Cancer Center shared a post on X:
“A new AI-based tool, developed by a team of researchers from MSK and The Tisch Cancer Institute, could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors – a type of immunotherapy – using only routine blood tests and clinical data.
Learn more about how this effort could make the treatment more accessible around the globe.”
More posts featuring Memorial Sloan Kettering Cancer Center.